The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer

Xiaoshun Shi, Xiaoying Dong, Sylvia Young, Allen Menglin Chen, Xiguang Liu, Zhouxia Zheng, Kailing Huang, Di Lu, Siyang Feng, Grant Morahan, Kaican Cai

Research output: Contribution to journalArticle

Abstract

Background: Small cell lung cancer (SCLC) is a highly invasive and lethal neuroendocrine tumor. Antiangiogenic drugs have been reported in the treatment of SCLC. We aimed to provide a comprehensive evaluation of the impact of angiogenic inhibitors on SCLC survival using network meta-analysis. Methods: The impact of five angiogenesis inhibitors, that is, vandetanib (Van), bevacizumab (Bev), Rh-endostatin (End), sunitinib (Sun), and thalidomide (Tha), on progression-free survival (PFS) and overall survival (OS) was evaluated by conducting a network meta-analysis. RNA sequencing data were downloaded from publicly available databases. Results: Nine phase II and III randomized controlled trials (RCTs), that involved 1599 participants, that investigated angiogenesis inhibitors in the treatment of SCLC were included in this meta-analysis. Sun and Bev achieved better PFS than Tha (Bev VS. Tha, HR = 0.88, 95% CI: 0.79-0.98, Sun VS. Tha, HR = 0.80, 95% CI: 0.65-1.00). Moreover, Sun and Bev were superior to placebo in terms of PFS (Bev VS. Placebo, HR = 0.89, 95%CI: 0.81-0.97, Sun VS. Placebo, HR = 0.81, 95% CI: 0.66-1.00). Based on this study, we found no significant difference of OS of SCLC. The angiogenesis pathway and expression of target genes were globally deactivated in SCLC tissue. Conclusion: Results of this network meta-analysis indicate that the PFS outcome of SCLC with Sun or Bev drugs is superior to that of Tha. The improved therapeutic impact of angiogenesis inhibitors on SCLC needs more evidence, such as long-term observation in clinical trials, to be validated.

Original languageEnglish
JournalCancer Medicine
DOIs
Publication statusE-pub ahead of print - 21 Aug 2019

Fingerprint

Angiogenesis Inhibitors
Small Cell Lung Carcinoma
Thalidomide
Survival
Disease-Free Survival
Placebos
Endostatins
RNA Sequence Analysis
Neuroendocrine Tumors
Pharmaceutical Preparations
Meta-Analysis
sunitinib
Bevacizumab
Therapeutics
Randomized Controlled Trials
Observation
Clinical Trials
Databases
Gene Expression

Cite this

Shi, Xiaoshun ; Dong, Xiaoying ; Young, Sylvia ; Chen, Allen Menglin ; Liu, Xiguang ; Zheng, Zhouxia ; Huang, Kailing ; Lu, Di ; Feng, Siyang ; Morahan, Grant ; Cai, Kaican. / The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer. In: Cancer Medicine. 2019.
@article{0d5505b80de6455db0aa726c28c2f164,
title = "The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer",
abstract = "Background: Small cell lung cancer (SCLC) is a highly invasive and lethal neuroendocrine tumor. Antiangiogenic drugs have been reported in the treatment of SCLC. We aimed to provide a comprehensive evaluation of the impact of angiogenic inhibitors on SCLC survival using network meta-analysis. Methods: The impact of five angiogenesis inhibitors, that is, vandetanib (Van), bevacizumab (Bev), Rh-endostatin (End), sunitinib (Sun), and thalidomide (Tha), on progression-free survival (PFS) and overall survival (OS) was evaluated by conducting a network meta-analysis. RNA sequencing data were downloaded from publicly available databases. Results: Nine phase II and III randomized controlled trials (RCTs), that involved 1599 participants, that investigated angiogenesis inhibitors in the treatment of SCLC were included in this meta-analysis. Sun and Bev achieved better PFS than Tha (Bev VS. Tha, HR = 0.88, 95{\%} CI: 0.79-0.98, Sun VS. Tha, HR = 0.80, 95{\%} CI: 0.65-1.00). Moreover, Sun and Bev were superior to placebo in terms of PFS (Bev VS. Placebo, HR = 0.89, 95{\%}CI: 0.81-0.97, Sun VS. Placebo, HR = 0.81, 95{\%} CI: 0.66-1.00). Based on this study, we found no significant difference of OS of SCLC. The angiogenesis pathway and expression of target genes were globally deactivated in SCLC tissue. Conclusion: Results of this network meta-analysis indicate that the PFS outcome of SCLC with Sun or Bev drugs is superior to that of Tha. The improved therapeutic impact of angiogenesis inhibitors on SCLC needs more evidence, such as long-term observation in clinical trials, to be validated.",
keywords = "angiogenesis inhibitors, network meta-analysis, randomized controlled trial, small cell lung cancer, target drugs",
author = "Xiaoshun Shi and Xiaoying Dong and Sylvia Young and Chen, {Allen Menglin} and Xiguang Liu and Zhouxia Zheng and Kailing Huang and Di Lu and Siyang Feng and Grant Morahan and Kaican Cai",
year = "2019",
month = "8",
day = "21",
doi = "10.1002/cam4.2462",
language = "English",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley & Sons",

}

The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer. / Shi, Xiaoshun; Dong, Xiaoying; Young, Sylvia; Chen, Allen Menglin; Liu, Xiguang; Zheng, Zhouxia; Huang, Kailing; Lu, Di; Feng, Siyang; Morahan, Grant; Cai, Kaican.

In: Cancer Medicine, 21.08.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer

AU - Shi, Xiaoshun

AU - Dong, Xiaoying

AU - Young, Sylvia

AU - Chen, Allen Menglin

AU - Liu, Xiguang

AU - Zheng, Zhouxia

AU - Huang, Kailing

AU - Lu, Di

AU - Feng, Siyang

AU - Morahan, Grant

AU - Cai, Kaican

PY - 2019/8/21

Y1 - 2019/8/21

N2 - Background: Small cell lung cancer (SCLC) is a highly invasive and lethal neuroendocrine tumor. Antiangiogenic drugs have been reported in the treatment of SCLC. We aimed to provide a comprehensive evaluation of the impact of angiogenic inhibitors on SCLC survival using network meta-analysis. Methods: The impact of five angiogenesis inhibitors, that is, vandetanib (Van), bevacizumab (Bev), Rh-endostatin (End), sunitinib (Sun), and thalidomide (Tha), on progression-free survival (PFS) and overall survival (OS) was evaluated by conducting a network meta-analysis. RNA sequencing data were downloaded from publicly available databases. Results: Nine phase II and III randomized controlled trials (RCTs), that involved 1599 participants, that investigated angiogenesis inhibitors in the treatment of SCLC were included in this meta-analysis. Sun and Bev achieved better PFS than Tha (Bev VS. Tha, HR = 0.88, 95% CI: 0.79-0.98, Sun VS. Tha, HR = 0.80, 95% CI: 0.65-1.00). Moreover, Sun and Bev were superior to placebo in terms of PFS (Bev VS. Placebo, HR = 0.89, 95%CI: 0.81-0.97, Sun VS. Placebo, HR = 0.81, 95% CI: 0.66-1.00). Based on this study, we found no significant difference of OS of SCLC. The angiogenesis pathway and expression of target genes were globally deactivated in SCLC tissue. Conclusion: Results of this network meta-analysis indicate that the PFS outcome of SCLC with Sun or Bev drugs is superior to that of Tha. The improved therapeutic impact of angiogenesis inhibitors on SCLC needs more evidence, such as long-term observation in clinical trials, to be validated.

AB - Background: Small cell lung cancer (SCLC) is a highly invasive and lethal neuroendocrine tumor. Antiangiogenic drugs have been reported in the treatment of SCLC. We aimed to provide a comprehensive evaluation of the impact of angiogenic inhibitors on SCLC survival using network meta-analysis. Methods: The impact of five angiogenesis inhibitors, that is, vandetanib (Van), bevacizumab (Bev), Rh-endostatin (End), sunitinib (Sun), and thalidomide (Tha), on progression-free survival (PFS) and overall survival (OS) was evaluated by conducting a network meta-analysis. RNA sequencing data were downloaded from publicly available databases. Results: Nine phase II and III randomized controlled trials (RCTs), that involved 1599 participants, that investigated angiogenesis inhibitors in the treatment of SCLC were included in this meta-analysis. Sun and Bev achieved better PFS than Tha (Bev VS. Tha, HR = 0.88, 95% CI: 0.79-0.98, Sun VS. Tha, HR = 0.80, 95% CI: 0.65-1.00). Moreover, Sun and Bev were superior to placebo in terms of PFS (Bev VS. Placebo, HR = 0.89, 95%CI: 0.81-0.97, Sun VS. Placebo, HR = 0.81, 95% CI: 0.66-1.00). Based on this study, we found no significant difference of OS of SCLC. The angiogenesis pathway and expression of target genes were globally deactivated in SCLC tissue. Conclusion: Results of this network meta-analysis indicate that the PFS outcome of SCLC with Sun or Bev drugs is superior to that of Tha. The improved therapeutic impact of angiogenesis inhibitors on SCLC needs more evidence, such as long-term observation in clinical trials, to be validated.

KW - angiogenesis inhibitors

KW - network meta-analysis

KW - randomized controlled trial

KW - small cell lung cancer

KW - target drugs

UR - http://www.scopus.com/inward/record.url?scp=85070912352&partnerID=8YFLogxK

U2 - 10.1002/cam4.2462

DO - 10.1002/cam4.2462

M3 - Article

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

ER -